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ABSTRACT
canSAR (http://cansar.icr.ac.uk) is a public integra-
tive cancer-focused knowledgebase for the support
of cancer translational research and drug discovery.
Through the integration of biological, pharmaco-
logical, chemical, structural biology and protein
network data, it provides a single information portal
to answer complex multidisciplinary questions
including—among many others—what is known
about a protein, in which cancers is it expressed or
mutated, and what chemical tools and cell line
models can be used to experimentally probe its
activity? What is known about a drug, its cellular sen-
sitivity profile and what proteins is it known to bind
that may explain unusual bioactivity? Here we
describe major enhancements to canSAR including
new data, improved search and browsing capabilities
and new target, cancer cell line, protein family and 3D
structure summaries and tools.
The translational research and drug discovery communities
are still grappling with the mixed blessing of the deluge of
data that has been the result of international coordinated
efforts including the International Cancer Genome
Consortium (1), the International Molecular Exchange
(IMEx) protein interaction data consortium (2) and
cellular drug proﬁling (3,4), and increasingly powerful
sequencing and screening technologies. Rapidly
accelerating data growth is spanning the ﬁelds of
genomics (1,5,6), chemical biology (4), structural biology
(7) and systems biology (2). Many powerful resources now
exist to allow users to interrogate these data, e.g. (8,9).
While some integrate several data types such as gene ex-
pression with compound activities (10,11) or different types
of omics data (8), these resources typically focus their
strengths on particular core areas such as genomics (8),
drug action (9,12) or expression correlations (10).
canSAR, initially described in 2011 (13), was the ﬁrst—
and to our knowledge, remains the only—resource to in-
tegrate disparate and multidisciplinary data spanning
biology, pharmacology, chemistry, structural biology
and protein networks. Importantly, it was designed not
merely to link and cross-reference these scientiﬁc
domains, but to enable researchers to reach key informa-
tion rapidly and answer multidisciplinary questions re-
gardless of their background or areas of expertise. Since
it was initially launched, canSAR has been visited by
>32 000 users from >100 countries. The user-base
includes biologists, chemists, structural biologists and clin-
icians. Here we describe major updates to canSAR data
and its functionality.
DATA CONTENT AND GROWTH
canSAR contains the full complement of the human
proteome as well as 16 332 proteins from 2136 model
organisms that fall into 8631 major protein families. It
contains annotations and data for >11 000 cell lines,
both cancer and nontransformed cell lines, and 3690
patient-derived tissue samples with >10 000 experimental
result sets (for breakdown see http://cansar.icr.ac.uk/
cansar/data-sources/). The fully searchable 2D structure
and annotation for nearly one million small molecule
drugs and chemical probes have collectively >8 000 000
experimental bioactivities as well as 10 million calculated
properties. There are >93 000 3D structures for 31 130
proteins, collectively containing 16 700 ligands
determined in complex with a protein. We have
annotated and classiﬁed these ligands into different
classes as described below and identiﬁed ca 16 000
ligands that are functionally relevant. All ligands have
3D ligand-interaction maps in canSAR. In addition to
the collated and annotated data, canSAR contains
curation and additional analyses including 4544 3D-
structure–based, 8197 Ligand-based and 9446
protein-network–based druggability results for human
proteins. Importantly, all data from all areas of
*To whom correspondence should be addressed. Tel: +44 208 722 4000; Email: bissan.al-lazikani@icr.ac.uk
The authors wish it to be known that, in their opinion, the ﬁrst two authors should be regarded as Joint First Authors.
D1040–D1047 Nucleic Acids Research, 2014, Vol. 42, Database issue Published online 3 December 2013
doi:10.1093/nar/gkt1182
 The Author(s) 2013. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which
permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 1. Global keyword searching: (a) the single global search capability that enables keyword searches to be performed across (b) genes and
proteins, (c) cell lines (d) 3D structures and (e) compounds. The results are displayed in tabular forms with icons representing the availability of data
such as cancer mutations and bioactive chemical probes. The user can sort the results based on these data. (f) New browsing functionality that allows
exploring canSAR’s content through browsing genes and proteins, protein families, 3D structures or drugs and compounds. For example, (g) protein
families have a summary feature where the user can sort and select families based on the types of data available. (h) Molecular targets, compounds
and cell lines may be browsed by name.
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research are seamlessly integrated and are fully
referenced to their original sources and speciﬁc publica-
tions where available to ensure that researchers can
rapidly identify the original source of the information
without complex and lengthy searching.
NEW SEARCH AND BROWSING CAPABILITIES
canSAR now has a single global search capability
(Figure 1a) that enables keyword searches to be performed
across the system, thus speeding up the retrieval of data.
Additional, object-speciﬁc search capabilities such as
protein sequence and chemical structure searches remain
in place.
Browsing canSAR data can now be accomplished
through protein/gene name alphabetical dictionaries,
protein-families, 3D structure and compound dictionaries
(Figure 1f). These new search and browsing capabilities
allow users to explore the data in canSAR in a broader
way, e.g. the user can rank members of a particular
protein family based on the availability of reported
cancer mutations, bioactive chemical probes, druggability
or can browse through all cell lines from a particular tissue
type.
Figure 2. (a) The molecular target wiki page provides a complete, human readable, summary of the data stored for a particular protein and contains
links to more in-depth data. The header icons indicate the types of information that are available, such as mutations, 3D structures and bioactivities
as well as showing if the protein is an approved drug target. Detailed information such as drugs, (b) domain and protein 3D-structure availability, (c)
druggability prediction using three alternative approaches as well as (d) tumor-tissue and cell line gene expression and mutation can be explored in
detail and linked through to original sources. (e) Protein interaction networks are annotated with the chemogenomic data summaries from canSAR
enabling exploration of deregulated and/or druggable network members. (f) Cell line data matrix provides a single view on mutation, expression,
copy number variation and RNAi studies, where available, in one tabular summary.
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TARGET SYNOPSES
One of the most popular uses of canSAR is retrieving
instant summaries about a particular target of interest.
To enhance this ability, we have developed a new ‘wiki’-
style summary page (Figure 2a) that distils the key infor-
mation about the target in a human-readable summary
form and covers function, cellular localization, drugs
and clinical candidates, cancer mutations, RNAi data,
expression levels in cancer and nontransformed cell lines
and drug or chemical probe bioactivity information
among others. Each section is linkable and explorable
with drill-down capabilities. The cell-line matrix displays
all available information for the speciﬁc target in all cell
lines, so in one table, the user can see the mutation state,
expression level, and, where it exists, RNAi information
(Figure 2f). The interactive protein-interaction networks
provide a powerful resource that not only identiﬁes
protein interactions of the target of interest, but also
provides chemical biology annotation and genomic infor-
mation in an ‘at-a-glance’ form so that the user can im-
mediately identify any drug targets in the network, or
targets with known bioactive chemical probes, that are
RNAi screen hits or that have known mutations in
cancer (Figure 2e). Each protein in the network is
colored according to its chemical tractability, thus high-
lighting proteins within the immediate network of the
target of interest that would be most amenable to drug
discovery.
CELL-LINE SYNOPSES
We have developed a synopsis page for each cell line in
canSAR (Figure 3a) covering cancer and nontransformed
cell lines. These cell-line synopses summarize key
Figure 3. The new Cell Line synopsis summarizes the data stored about particular cell lines. (a) The overview page presents the highlights including
a banner of icons indicating availability and status of different data such as mutations, bioactivities, RNAi and gene expression. All data can be
explored in detail including (b) reported mutations, (c) listing of ‘genetically’ similar cell lines based on mutational status, (d) highest and lowest
expressed genes and (e) drug sensitivity proﬁles compiled from different sources.
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information about a cell line including its tissue of
origins, key mutations and gene copy-number variations,
the highest and lowest expressing genes, the number and
the activity of drugs or chemical probes tested against it,
among other descriptors. In addition, detail is provided
including full mutation reports and comparison with
other cell lines (Figure 3) to enable rapid identiﬁcation
of genetically similar or complementary cells, drug/
chemical probes sensitivity proﬁles and RNAi experimen-
tal data summaries.
PROTEIN FAMILY SYNOPSES
It is often useful to view the information around a target
family as opposed to individual targets. This can be the
case when multiple family members are involved in the
same biological process or when, say in a drug discovery
context, the chemical modulation of certain family
members needs to be avoided to prevent adverse reactions.
To enable the full chemogenomic exploration of protein
families, we have developed protein family synopsis pages
(Figure 4) that summarize the number of family members,
the number of members that are druggable, that have bio-
active compounds and that are known to have mutations
in cancer. The family deﬁnitions for these pages are cur-
rently obtained from Uniprot (14) annotations with plans
to expand them into Pfam (15) families in the near future.
All the numbers are then linkable to the full detailed in-
formation to enable viewing and sorting family members,
their bioactive compounds or their 3D structures
(Figure 4).
canSAR-3D
3D structure is a powerful tool in understanding the mo-
lecular mechanisms of disease and the design and develop-
ment of new drugs. As well as having access to the large
number of protein structures (>93 000) in the Protein Data
Bank (PDB) (7), it is important to know how the different
structures compare, what domains within the protein are
structurally characterized, what ligands or drugs they bind
and where druggable pockets potentially exist. canSAR-
3D, the 3D structural component of canSAR, contains
annotated PDB structures where each structure is linked
to the protein and full genomic information, on the one
hand, and the full chemical information for its ligand on
the other (Figure 5). We have curated the ligands in the
PDB into ﬁve categories to better distinguish those that
are genuine small molecule endogenous ligands or
chemical modulators of protein function from biologically
unimportant small molecules such as surfactants. The
categorization of small molecule ligands is computationally
assigned based on the presence of >6 non-Hydrogen
atoms. Exceptions to this rule and the surfactants in this
list are further classiﬁed bymanual curation. There is a per-
protein structural summary page that graphically repre-
sents the structures available for a protein and regions
they cover, together with structures of homologues depend-
ing on similarity criteria set by the user (Figure 5a).
Figure 4. The Protein Family synopsis summarizes the data held about a particular family, including the number of druggable members, the number
of members that have bioactive compounds and those members that are known to have mutations in cancer. These are linked directly to the full
chemical bioactivity data and their publications and full mutation data as well as other annotation. All subfamilies and individual proteins can be
reached through an interactive family tree.
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The full structural complement for each protein is dis-
played in an interactive browser that allows comparison of
the structures and viewing of ligand-interaction maps
(Figure 5b, c). 3D structure superposition may also be
carried out on-the-ﬂy. The 3D-druggability scores
(12,16) for all identiﬁed pockets within each structure
are automatically calculated and updated in canSAR on
a weekly basis. For some families of special interest, we
Figure 5. Snapshots of some components of canSAR-3D. (a) The 3D explorer shows all structures available for a target (in this case EGFR) and
allows ﬁltering based on the availability of bound drugs (as shown) or other ligands, and on structure-based druggability. (b) Ligand interaction
maps, 3D structural inspection and (c) superpositions viewers are available and all are linked seamlessly to chemical bioactivity and protein, genetic
and functional data.
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are introducing additional curation and analyses. For
example, protein kinase structures are tagged with the
activation state of the structure (Figure 5).
USING canSAR
Single portal for multidisciplinary data
Users often utilize canSAR as a single-point portal to
access broad data available for a gene, protein, drug or
cell line. The target, compound and cell line synopses are
typical access points for these. More complex use cases
typically performed in canSAR include the following
examples.
Identifying tools for probing a target’s activity
For a gene or protein of interest, the user can identify
available evidence for disease association through
altered mutation or expression in patient tissue on the
target synopsis. In this same page, the user can identify
which cancer cell lines will be useful to use as model
systems to study this target, and what are the genetic
states of these cellular models. Furthermore, using
both the target synopsis and bioactivity exploration, or
the cell line synopses, the user can identify which drugs
have shown activity against their target or their model cell
lines.
Prioritizing lists of genes for further experiments
For a list of genes from a functional RNAi screen, their
proteins can be assessed for ‘druggability’ based on up-to-
date structural and chemical information to identify which
are the most druggable targets and also what chemical
probes have been published for them. These can be
investigated individually through the target synopses or
in batches of up to 500 genes using the Cancer
Protein Annotation Tool in canSAR. This tool provides
the user with a spreadsheet summarizing the evidence
for druggability, and the availability of structural and
chemical probes.
What is known about a cell line of interest
Using the cell line synopsis, users can explore the genetic
and transcriptional make up of a cell line. The user can
also identify other cell lines with shared mutations as well
as examine drug sensitivity proﬁles and identify which
drugs a cell is sensitive or resistant to.
Multidisciplinary network analysis
For a target of interest, the user can utilize the protein
interaction network to identify druggable targets within
the immediate network of the protein of interest. Also,
in the same place, the users can identify whether these
network neighbors have been reported as hits in a
cancer RNAi screen or whether they are mutated in
cancer.
CONCLUDING REMARKS AND FUTURE
DEVELOPMENT
Since its initial release, canSAR has grown both in content
and functionality. Through the integrated data in
canSAR, users can rapidly answer complex scientiﬁc ques-
tions as exempliﬁed above. Furthermore, examples of
using canSAR in this way to identify novel druggable
cancer targets have recently been described (16). These
and some further examples and use cases are published
on the canSAR online documentation pages (http://
cansar.icr.ac.uk/cansar/documentation/) and we will be
adding to them over time.
Future plans for canSAR include further data growth,
especially around the annotation of patient-derived ex-
perimental data, cancer clinical trial information,
increased integration with the IMEx consortium (2) for
the annotation of protein-network data and introducing
tissue imaging data. Furthermore, a number of additional
expert tools are planned including the introduction of
Kaplan–Meier plot tools to identify correlation between
underlying genetics and patient, mutation impact
summaries and pathway exploration tools—all of which
have been requested by our users. We will also develop
interactive gene/protein visualization tools, speciﬁc cancer
disease browsing and cancer clinical trial navigation tools
in addition to further enhancements and functionality in
response to feedback from our users.
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